Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
Form 3 Overview: Nuvalent, Inc. (NUVL) filed an Initial Statement of Beneficial Ownership for Ms. Christy J. Oliger on 06/20/2025, reporting an event date of 06/18/2025.
Key Details:
- Reporting Person: Christy J. Oliger
- Relationship to Issuer: Director (no other roles indicated)
- Beneficial Ownership: The filer explicitly states “No securities are beneficially owned.”
- Filing Type: Form filed by one reporting person; accompanied by a Power of Attorney (Exhibit 24) signed by attorney-in-fact Nathan N. McConarty.
Investor Takeaway: A Form 3 signals an insider’s entry into the company’s reporting framework. However, because the form shows zero shares owned, there is no immediate dilution, concentration change, or valuation signal. The filing is largely administrative, confirming Ms. Oliger’s board position and future reporting obligations under Section 16(a).
Nuvalent, Inc. (NASDAQ: NUVL) filed a Form 8-K covering two corporate-governance items dated June 18, 2025.
Board change (Item 5.02): The Board unanimously elected Christy J. Oliger as an independent Class III director, effective immediately. She will serve until the 2027 annual meeting and join the Audit Committee. Compensation aligns with the existing non-employee director policy and includes:
- Initial stock option for 6,119 shares at an exercise price of $75.53, vesting monthly over three years.
- Initial RSU award of 3,971 shares, vesting annually over three years.
- Annual cash retainers and ongoing equity grants as stipulated in the policy.
2025 Annual Meeting results (Item 5.07): Quorum was strong with 64.38 million votes representing 97.01 % of outstanding shares. Outcomes were:
- Director elections: Grant Bogle (99.87 % support); James R. Porter, Ph.D. (99.78 %); Anna Protopapas (86.27 %).
- Say-on-pay: Approved with 83.8 % (53.52 m for, 10.36 m against).
- Auditor ratification: KPMG LLP re-approved with 99.98 % support.
Investor take-away: The filing is largely procedural. The addition of an experienced independent director strengthens oversight, while voting results confirm broad shareholder support for existing leadership and compensation structure.